Tango Therapeutics Inc [TNGX] stock is trading at $6.77, saw in change for the day. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TNGX shares have gain 11.17% over the last week, with a monthly amount glided 41.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tango Therapeutics Inc [NASDAQ: TNGX] stock has seen the most recent analyst activity on July 17, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $19. On February 12, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $18 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $16 on December 08, 2023. H.C. Wainwright upgraded its rating to a Buy but $10 remained the price target by the analyst firm on October 20, 2022. SVB Leerink started tracking with a Outperform rating for this stock on September 20, 2021, and assigned it a price target of $25.
Tango Therapeutics Inc [TNGX] stock has fluctuated between $1.03 and $12.02 over the past year. Currently, Wall Street analysts expect the stock to reach $14.67 within the next 12 months. Tango Therapeutics Inc [NASDAQ: TNGX] shares were valued at $6.77 at the most recent close of the market. An investor can expect a potential return of 116.69% based on the average TNGX price forecast.
Analyzing the TNGX fundamentals
Tango Therapeutics Inc [NASDAQ:TNGX] reported sales of 40.99M for the trailing twelve months, which represents a drop of -16.67%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -3.56%, Pretax Profit Margin comes in at -3.22%, and Net Profit Margin reading is -3.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.63 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Tango Therapeutics Inc’s Current Ratio is 6.26. Further, the Quick Ratio stands at 6.26, while the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 17.90, the price to book ratio is 4.39.
Transactions by insiders
Recent insider trading involved Barry Douglas, General Counsel, that happened on Feb 04 ’25 when 2774.0 shares were sold. General Counsel, Barry Douglas completed a deal on Feb 05 ’25 to sell 2556.0 shares. Meanwhile, Chief Financial Officer Beckman Daniella sold 4284.0 shares on Feb 04 ’25.
